Teva (NYSE:TEVA) today announced that its FDA-approved generic EpiPen Jr. auto-injector is available in the U.S.
The device wholesales to most retail pharmacies in packs of two for $300, or $150 per pen. Teva’s product is less than half the cost of Mylan’s non-generic EpiPen Jr., which lists at $643.89 per two-pack at Drugs.com.
”We’re pleased to provide access to epinephrine injection (auto-injector) in two strengths for patients who may experience life-threatening allergic emergencies,” EVP & head of North America commercial Brendan O’Grady said in prepared remarks. “We will continue working to ensure availability of both strengths in the U.S. and plan to accelerate production to meet the urgent need for this medicine.”
In November 2018, Israel-based Teva launched its generic EpiPen for $300 – the same price as the generic version Mylan released in December 2016. In February of this year, Teva said it expected its generic EpiPen to claim 25% of the U.S. market.
